Investigating the Therapeutic Potential of MSC-EVs in Neonatal HIE.
Perinatal hypoxic-ischemic encephalopathy (HIE) is a severe brain injury in newborns and could cause long-term neurological developmental disorders. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are increasingly regarded as an effective cell-free therapeutic approach due to their low immunogenicity, natural ability to cross the blood-brain barrier, and engineerable properties. This review indicates that MSC-EVs can achieve better therapeutic effects by specifically regulating the immune response and promoting repair at different stages of neuroinflammation. It systematically summarizes engineering optimization strategies to enhance the therapeutic effect of MSC-EVs, including reprogramming EV components via hypoxia or drug pretreatment and improving EV biological activity and tissue bioavailability through 3D culture combined with biomaterial delivery systems. Additionally, it analyzes the efficacy, advantages, and limitations of different administration routes for the treatment of cerebral ischemia-hypoxia diseases. Finally, it discusses the limitations of MSC-EVs in the treatment of HIE and future research directions, providing a comprehensive theoretical basis for the clinical translation of MSC-EVs as a targeted treatment for neonatal HIE.
Authors
- Mengsi Lin (ORCID: https://orcid.org/0000-0002-6789-872X)
- Maorong Jiang
- Dengbing Yao (ORCID: https://orcid.org/0000-0002-5177-0318)
- Yi Yao (ORCID: https://orcid.org/0000-0003-2020-8565)
- Min Cai (ORCID: https://orcid.org/0000-0002-4573-0870)
- Xi Gu
- Hui Xu
- Yiming Xia
Institutions
- Nantong University (CN)
- Nantong Maternity and Child Health Hospital (CN)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-17
- DOI
- https://doi.org/10.2174/011574888x498122261113115058
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00